Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind(®))

Clinica Chimica Acta

Volumn 283, Issue 1-2, 1999, Pages 159-169

  Jortani, Saeed A ^a   Pinar, Asli ^a   Johnson, Nancy A ^a   Valdes Jr , Roland ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Digibind( ); Digoxin; Fab fragments; Immunoassays

Indexed keywords

DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT;

ARTICLE; IMMUNOASSAY; PRIORITY JOURNAL; SERUM; ULTRAFILTRATION;

ADULT; ANTIDOTES; DIGOXIN; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; OVERDOSE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; ULTRAFILTRATION;

EID: 0032784547     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00043-1     Document Type: Article

References (24)

1. Smith T.W., Haber E., Yeatman L., Butler V.P. Reversal of advanced digoxin intoxication with FAB fragments of digoxin-specific antibodies. New Engl. J. Med. 294:1976;797-800.
2. Wegner T.L., Butler V.P., Haber E., Smith T.W. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J. Am. Coll. Cardiol. 5:1985;118A-123A.
3. Smith T.W., Butler V.P., Haber E., et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments, experience in 26 cases. New Engl. J. Med. 307:1982;1357-1362.
4. Noel F., Fagoo M., Godfraind T. A comparison of the affinities of rat (Na+-K+)-ATPase isoenzymes for cardioactive steroids, role of lactone ring, sugar moiety and Kcl concentration. Biochem. Pharmacol. 40:1990;2611-2616.
5. Antman E.M., Wenger T.L., Butler V.P. Jr, Haber E., Smith T.W. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Circulation. 81:1990;1744-1752.
6. Ujhelyi M.R., Robert S. Pharmacokinetic aspect of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin. Pharmacokinet. 28:1995;483-493.
7. Ujhelyi M.R., Green P.J., Cummings D.M., Robert S., Vlasses P.H., Zarowitz B.J. Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin Fab antibodies. Ther. Drug Monitor. 14:1992;147-154.
8. Rainey P.M. Effects of digoxin immune Fab (ovine) on digoxin immunoassays. Am. J. Clin. Pathol. 92:1989;779-786.
9. Miller J.J., Straub R.W., Valdes R. Jr. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Ther. Drug Monitor. 18:1996;65-72.
10. Honda S.A.A., Rios C.N., Murakami L., Morita T., Scottolini A.G., Bhagavan N.V. Problems in determining levels of free digoxin treated with digoxin immune Fab. J. Clin. Lab. Anal. 9:1995;407-412.
11. Dodds H.M., Norris R.L.G., Johnson A.G., Pond S.M. Evaluation and comparison of the TDxII, Stratus, and OPUS digoxin assays. Ther. Drug Monitor. 17:1995;68-74.
12. Ujhelyi M.R., Cummings D.M., Green P., Ellison M.J., Vlasses P.H. Effect of digoxin Fab antibodies on five digoxin immunoassays. Ther. Drug Monitor. 12:1990;288-292.
13. Lemon M., Andrews D.J., Binks A.M., et al. Concentrations of free serum digoxin after treatment with antibody fragments. Br. Med. J. 295:1987;1520-1521.
14. Ruiz R., Borque L., Soria A.G., Cordova M.A., Asolo B. Evaluation of an immunoturbidimetric assay of serum digoxin without sample pretreatment. Eur. J. Clin. Chem. Clin. Biochem. 33:1995;171-175.
15. Roche Diagnostics Systems, Roche-TDM On Line Automated Assays for TDM: (digoxin package insert), Roche Diagnostics Systems, Somerville, NJ, 1994.
16. Abbott AxSYM System, (digoxin package insert), Abbott Laboratories, Diagnostics Division, Abbott Park, IL, 1995.
17. Azzazy H.M., Duh S.H., Maturen A., et al. Multicenter study of Abbott AxSYM Digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive factors. Clin. Chem. 43:1997;1635-1640.
18. Dade Behring Diagnostics, Stratus Digoxin Fluorometric Enzyme Immunoassay (digoxin package insert), Dade Behring Diagnostics, Newark, DE, 1993.
19. Chiron Diagnostics, ACS Automated Chemiluminescence System (digoxin package insert), Chiron Diagnostics, Medfield, MA,1994.
20. Valdes R. Jr, Miller J.J. Increasing the specificity of immunoassays. J. Clin. Immunoassay. 15:1992;87-96.
21. Jortani S.A., Valdes R. Jr. Digoxin and its related endogenous factors. Crit. Rev. Clin. Lab. Sci. 34:1997;225-274.
22. Henderson A.R. Chemistry with confidence: should clinical chemistry require confidence intervals for analytical and other data? Clin. Chem. 39:1993;929-935.
23. Valdes Jr R, Jortani SA. Monitoring unbound digoxin in patients treated with anti-digoxin antigen-binding fragments: A model for the future? Clin. Chem. 1998;44 (in press).
24. Valdes R. Jr, Jortani S.A., Gheorghiade M. Standards of laboratory practice: Cardiac drug monitoring. Clin. Chem. 1998;1096-1109.